Sanofi
4Q Revenues: €10.9 billion (+2%)
4Q Loss: €555 million (-118%)
FY Revenues: €43.1 billion (flat)
FY Earnings: €5.4 billion (-36%)
Comments: Specialty Care sales were up 13.7% in the quarter driven by Dupixent with sales of €2.99 billion, up 31%, and ALTUVIIIO launches, offsetting competition from generics of Aubagio in all key markets. Aubagio sales were down 74% to €121 million in the quarter. Myozyme sales were down 20% to €160 million. Nexviazyme sales were up 115% to €131 million in the quarter.
 
Vaccines sales increased 21% mainly due to the unprecedented uptake of RSV vaccine Beyfortus, reaching €410 million in the second quarter of its launch, offset by lower Influenza vaccines sales and COVID-19 vaccines. Influenza vaccines sales were down 4% to €741 million. 
Polio/Pertussis/Hib vaccines sales were up 3% to €434 million. Meningitis, Travel and endemic vaccines sales were up 10% to €242 million. Booster vaccines sales were down 1.4% to €139 million.
 
General Medicines declined 2% related to lower sales of Lantus and non-core asset divestment. Lantus sales were €277 million, down 24.9% in the quarter. Core assets sales increased 6.3% to €1.6 billion, mainly driven by the performance of Plavix, Toujeo, Rezurock, and Praluent partially offset by lower sales of Mozobil due to generic competition.

Biopharma business sales decreased 2.8% to €2.3 billion.